JAKARTA - PT Kalbe Farma Tbk will expand its business by acquiring PT Aventis Pharma. This step was taken by the company owned by the conglomerate Boenjamin Setiawan through the signing of a share purchase agreement with Sanofi Aventis Participations and Hoechst GMBH.

Based on information from Kalbe's Corporate Secretary Lukito Kurniawan Gozali, Monday, July 25, the share purchase agreement took place last July 22. "Kalbe as the buyer will receive the transfer of shares of Aventis Pharma from Sanofi Aventis and Hoechst", said Lukito.

Through this transaction, Kalbe will acquire 80 percent ownership of Aventis Pharma as well as distribution, license, and marketing rights for prescription drug and vaccine products owned by sellers in the territory of Indonesia.

Lukito added this transaction is expected to have a positive impact on the company's performance, especially in the prescription drug division. "Completion of the transaction still depends on the fulfillment of several requirements in the share purchase agreement", said Lukito.

Citing the site Sanofi.co.id, Aventis Pharma is a legal entity of Sanofi Indonesia that has been operating for more than 60 years. Sanofi Indonesia is an affiliate of Sanofi, a diversified global healthcare company based in France with a diverse portfolio of pharmaceutical products (prescription and generic drugs), vaccines, and consumer health products.

To date, Sanofi has a presence in more than 170 countries and is supported by 100,000 employees who work together to provide innovative treatments to improve the health and well-being of people around the world.


The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)